Pictet Asset Management (UK)’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,231,955
| Closed | -$105M | – | 1796 |
|
|
2020
Q3 | $105M | Sell |
1,231,955
-1,122,931
| -48% | -$56.8M | 0.16% | 170 |
|
|
2020
Q2 | $83.5M | Buy |
2,354,886
+973,520
| +70% | +$28.5M | 0.14% | 186 |
|
|
2020
Q1 | $18.6M | Buy |
1,381,366
+86,031
| +7% | +$1.45M | 0.04% | 388 |
|
|
2019
Q4 | $27.4M | Sell |
1,295,335
-484,481
| -27% | -$8.55M | 0.05% | 376 |
|
|
2019
Q3 | $23.6M | Buy |
1,779,816
+404,670
| +29% | +$5.95M | 0.05% | 361 |
|
|
2019
Q2 | $19.1M | Buy |
1,375,146
+133,795
| +11% | +$2.01M | 0.04% | 396 |
|
|
2019
Q1 | $23.8M | Buy |
1,241,351
+223,350
| +22% | +$3.6M | 0.05% | 366 |
|
|
2018
Q4 | $14.5K | Sell |
1,018,001
-19,080
| -2% | -$379K | 0.04% | 428 |
|
|
2018
Q3 | $21.6M | Sell |
1,037,081
-268,058
| -21% | -$6.35M | 0.05% | 401 |
|
|
2018
Q2 | $30.9M | Sell |
1,305,139
-294,970
| -18% | -$5.93M | 0.07% | 309 |
|
|
2018
Q1 | $23.4M | Sell |
1,600,109
-18,965
| -1% | -$310K | 0.06% | 353 |
|
|
2017
Q4 | $26.2M | Buy |
1,619,074
+517,611
| +47% | +$6.11M | 0.07% | 331 |
|
|
2017
Q3 | $15.4M | Buy |
+1,101,463
| New | +$11M | 0.04% | 411 |
|
Pictet Asset Management (UK)'s IMMU Position: Q4 2020 in Review
Pictet Asset Management (UK) sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 1,231,955 shares — an estimated $105M sold.
Pictet Asset Management (UK) first reported a position in IMMU in Q3 2017 and held it in 13 quarters. The position peaked at $105M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Pictet Asset Management (UK) reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Pictet Asset Management (UK) sold 1,231,955 Immunomedics Inc shares in Q4 2020, an estimated $105M.
- Pictet Asset Management (UK) first reported a position in Immunomedics Inc in Q3 2017 and held it in 13 quarters.
- Pictet Asset Management (UK)'s Immunomedics Inc position peaked at $105M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Pictet Asset Management (UK)'s 13F filing for Q4 2020, filed 16 Feb 2021.